On October 30th, a significant groundbreaking ceremony was held for an insulin formulation filling plant, which is a client project of Gan & Lee Pharmaceuticals (stock code: 603087.SH). The ceremony was attended by Malaysia's Deputy Prime Minister, YAB Dato’ Sri Haji Fadillah Bin Haji Yusof, and the former Second Finance Minister, Nor Mohamed Yakcop. Also present were Du Kai, the CEO of Gan & Lee Pharmaceuticals, and members of the company's Asia-Pacific international business team. Their presence highlighted the importance of the event, which symbolizes the deep cooperation between China and Malaysia in the biomedical industry.

During the ceremony, Mr. Du Kai engaged in friendly discussions with the Deputy Prime Minister and the former Finance Minister. The establishment of the factory will have a profound impact on alleviating the current medical resource shortage faced by Malaysia. Since August 2024, Malaysia has been experiencing a nationwide shortage of insulin. In this critical situation, Gan & Lee Pharmaceuticals, in collaboration with its Malaysian partner, promptly submitted a proposal to the Ministry of Health Malaysia. The proposal introduced a third-generation insulin analog that offers improved efficacy, safety, and convenience compared to the existing second-generation human insulin. The project is currently progressing actively and orderly Mr. Du highlighted Gan & Lee Pharmaceuticals’ dedication to patient care and its commitment to assisting the Malaysian government in overcoming the insulin shortage. “We are honored to contribute to the development of Malaysia’s local insulin production capabilities and to enhance the accessibility of medical treatments in the region,” he stated.

Over the past decade, Gan & Lee Pharmaceuticals has actively participated in the Belt and Road Initiative, establishing international partnerships and business operations in more than 20 countries and regions, including Turkey and Kazakhstan. The company has particularly gained substantial experience in localizing insulin production in large markets such as Indonesia, Brazil, Argentina, and Turkey. Gan & Lee Pharmaceuticals plans to leverage its production technology strengths and extensive experience in overseas technology transfer to facilitate the implementation of third-generation insulin filling technology for Malaysian enterprises. By introducing cost-effective products, the company aims to accelerate the shift in the Malaysian insulin market from second- to third-generation products. This collaboration not only strengthens business ties in the biomedical sector between the two countries but also positively impacts the health and well-being of the Malaysian population. Moving forward, Gan & Lee Pharmaceuticals remains committed to the spirit of the Belt and Road Initiative, working to deepen its relationships with global partners and to provide high-quality medications and services to patients worldwide.

About Gan & Lee

Gan & Lee Pharmaceuticals developed the first Chinese domestic insulin analog. Currently, Gan & Lee has six core insulin products, including five insulin analog varieties: long-acting glargine injection (Basalin^?), fast-acting lispro injection (Prandilin^?), fast-acting aspart injection (Rapilin^?), mixed protamine zinc lispro injection (25R) (Prandilin^?25), aspart 30 injection (Rapilin^?30), and one human insulin injection - mixed protamine human insulin injection (30R) (Similin^?30). The company has two approved medical devices in China, namely reusable insulin injection pen (GanleePen), and disposable pen needle (GanleeFine^?).

In China's 2024 National Insulin-Specific Centralized Procurement, Gan & Lee Pharmaceuticals ranked  first among all selected companies in terms of procurement demand for insulin analogs. The company is also making strides in international markets, with the disposable pen needle (GanleeFine^?) approved by the US Food and Drug Administration (FDA) in 2020 and received GMP inspection approval from the European Medicines Agency (EMA) in 2024. These achievements significantly boost Gan & Lee’s competitiveness in both international and domestic markets.

In the future, Gan & Lee will strive for comprehensive coverage in diabetes treatment. Moving forward with its mission to become a world-class pharmaceutical company, Gan & Lee will also actively develop new chemical entities and biological drugs, focusing on treatments for metabolic diseases, cardiovascular diseases, and other therapeutic areas.